Elicio is committed to transforming the lives of patients and their families by re-engineering the body’s immune response to cancer. By combining expertise in materials science and immunology, Elicio is engineering potent vaccines and immunotherapies to defeat an array of aggressive cancers.
Lymph nodes— where the immune response is orchestrated
Elicio was founded to expand and apply the ground-breaking Amphiphile technology invented and developed in the labs of Darrell Irvine, Ph.D., a Howard Hughes Medical Institute investigator and professor at the Koch Institute of Integrative Cancer Research at the Massachusetts Institute of Technology. Preclinical studies have demonstrated that Elicio’s Amphipihile vaccines target and concentrate in the lymph nodes, resulting in unprecedented tumor-specific immune responses and durable cures of aggressive tumor models in mice.
Elicio is currently ramping up for Phase 1 / 2 studies for VED-002 and VED-001. The programs consist of Amphiphile vaccines that have the potential to elicit powerful immune responses against KRAS, a mutation found in 90% of pancreatic cancers, and E6 and E7 antigens found in oropharyngeal carcinoma which makes up 30% of all HPV driven cancers.